1. Topical product development
NDA- New drug application
Safety – Toxicity study
Skin irritation
Cutaenous toxicity
Contact sensitization
Contact photodermititis
Percutaneous
absorption?Teratogen?
Efficacy: Two well controlled
clinical study
Manufacturing controls
Bioavailability studies
Invitro release studies
ANDA- Abbreviated New drug
application
Safety studies – skin
irritation, Cutaenous toxicity
Manufacturing controls
In-vivo bioequivalence or
clinical study
In-vitro release study
Inactive ingredients
qualitatively and
quantitatively “same”
s.gurubalaji@gmail.com